Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis

Drug Safety : an International Journal of Medical Toxicology and Drug Experience
P RieckmannEnrica Alteri

Abstract

Interferon-beta-1a (Rebif) is an established treatment for relapsing-remitting multiple sclerosis (MS) and haematological changes are commonly reported in clinical trials of this agent. The combined clinical trial and postmarketing safety database for subcutaneous interferon-beta-1a (Rebif) allows a comprehensive, retrospective assessment of both common and infrequent haematological effects associated with interferon-beta therapy. Haematological laboratory abnormalities were analysed from six randomised, controlled clinical trials of subcutaneous interferon-beta-1a in MS, five of which were placebo-controlled. Treatment data were collected from 2482 patients for up to 6 months, 1178 patients for up to 2 years and 786 patients for up to 6 years. Total interferon-beta-1a doses ranged from 22 microg once weekly to 44 microg three times weekly. Postmarketing surveillance data were also analysed. Treatment with interferon-beta-1a led to asymptomatic dose-related reductions in all cell lineages under investigation, predominantly white blood cells. The greatest differences between interferon-beta-1a therapy and placebo were seen for total leucocyte and neutrophil counts. At least two-thirds of patients affected by cytopenia experience...Continue Reading

References

Dec 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S ErnstoffJ M Kirkwood
Feb 1, 1994·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·T Vial, J Descotes
Mar 4, 1999·Journal of the Neurological Sciences·L DurelliG Aimo
Sep 18, 1999·Digestive Diseases and Sciences·A LandauG Tchernia
Feb 15, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·A Bayas, P Rieckmann
Jun 1, 2000·Australian and New Zealand Journal of Medicine·N D McDonald, M P Pender
Jul 6, 2000·Journal of Endocrinological Investigation·M RotondiC Carella
May 30, 2001·Lancet·G ComiUNKNOWN Early Treatment of Multiple Sclerosis Study Group
Jun 13, 2001·Neurology·UNKNOWN Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group
Jun 27, 2001·Neurology·UNKNOWN PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group.
Dec 12, 2001·Pediatrics International : Official Journal of the Japan Pediatric Society·B DikiciK Hasolat
Jan 5, 2002·American Journal of Hematology·S Rajan, H A Liebman
Mar 26, 2002·Digestive Diseases and Sciences·Abdurrahman SagirDieter Häussinger
Apr 2, 2002·The American Journal of Gastroenterology·Andrea Duchini
Apr 25, 2002·Journal of Pediatric Hematology/oncology·Hana HrstkováJaroslav Michálek
May 2, 2002·European Journal of Haematology·Clara CesanaEnrica Morra
Aug 13, 2002·Journal of Clinical Gastroenterology·Cécile BarelJérôme Dumortier
Nov 9, 2002·American Journal of Therapeutics·Ahmad Kamal Aslam, Tajveer Singh
Nov 27, 2002·Neurology·H PanitchUNKNOWN University of British Columbia MS/MRI Research Group
Mar 26, 2003·The American Journal of Gastroenterology·V A SevastianosE K Manesis
Aug 12, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Gordon S FrancisNeil Kaplowitz

❮ Previous
Next ❯

Citations

Aug 26, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·G CoppolaV Brescia Morra
May 27, 2010·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M A Sahraian, A Eshaghi
Aug 30, 2008·Neuropsychiatric Disease and Treatment·Francesco ManfredoniaFabio Monzani
Oct 7, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·David Murdoch, Katherine A Lyseng-Williamson
May 8, 2007·Expert Opinion on Drug Safety·Marcelo KremenchutzkyCarolina Rush
Jul 27, 2015·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Tatiana KoudriavtsevaCaterina Mainero
Sep 7, 2016·Expert Opinion on Pharmacotherapy·Nikolaos GrigoriadisGünther F L Hofbauer
Jun 6, 2007·Multiple Sclerosis : Clinical and Laboratory Research·G AlanogluS Kutluhan
Feb 6, 2017·Autoimmunity Reviews·Courtney S CasserlyLuc Vallières
Jan 18, 2012·Multiple Sclerosis : Clinical and Laboratory Research·G GiovannoniE Waubant
May 14, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Wangko LundströmAnna Fogdell-Hahn
Aug 31, 2018·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·A N BelovaA N Boyko
Mar 13, 2019·Neurology. Clinical Practice·Edward J FoxAaron Boster
Jul 22, 2018·Neurology. Neuroimmunology and Neuroinflammation·Xavier MontalbanFernando Dangond
Aug 21, 2019·Expert Opinion on Drug Safety·Clara G ChisariFrancesco Patti
Jun 1, 2014·BMJ Case Reports·David CachiaCarolina Ionete
May 18, 2020·Neurology. Neuroimmunology and Neuroinflammation·Joseph R BergerAmit Bar-Or
May 29, 2016·Metabolic Brain Disease·Meric A AltinozSinan Guloksuz
Jul 7, 2017·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·A K EllisL A Lee
Dec 6, 2018·Journal of Clinical Medicine·Tonia WoodberryAnne Brüstle
Jul 2, 2020·International Journal of Molecular Sciences·Mirre De BondtSofie Struyf
Sep 25, 2017·Current Neurology and Neuroscience Reports·Elena Grebenciucova, Amy Pruitt
Apr 11, 2019·Therapeutic Advances in Neurological Disorders·Luisa KlotzHeinz Wiendl
Apr 4, 2021·International Journal of Environmental Research and Public Health·Jacob M MillerMary Feller Davis
Jun 12, 2021·Frontiers in Immunology·Priyanka Devi-MarulkarFrédérique Michel
Apr 29, 2018·Revue neurologique·D Biotti, J Ciron

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. Discover the latest research on AIHA here.

Related Papers

Drug Safety : an International Journal of Medical Toxicology and Drug Experience
Gordon S FrancisNeil Kaplowitz
European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
R GoldPRISMS Study Group
© 2021 Meta ULC. All rights reserved